实体器官移植受者生殖器病变的患病率与类型
这项回顾性研究纳入2011年11月1日至2017年4月28日在学术转诊中心接受全身皮肤检查的496例实体器官移植受者,分为临床管理变更前(era 1,376例)和变更后(era 2,120例)两个时期。结果显示生殖器病变常见(53例,44.2%)但患者知晓率低(111/120,92.5%否认存在病变),12例原位鳞状细胞癌中8例(66.7%)高危HPV阳性。作者建议所有移植受者常规检查生殖器皮肤,深色皮肤类型患者应接受针对性早期检测和预防项目。
要点
- 496例移植受者中53例(44.2%)发现生殖器病变,但120例中111例(92.5%)否认存在病变。
- 12例原位鳞状细胞癌中8例(66.7%)高危HPV阳性,其中7例为HPV-16和HPV-18阳性。
- 作者建议所有移植受者常规进行生殖器皮肤检查,深色皮肤类型患者应接受针对性早期检测和预防项目。
核心结论
- 移植受者生殖器病变常见但患者知晓率低,所有移植受者应常规检查生殖器皮肤。
- 深色皮肤类型患者受皮肤生殖器恶性肿瘤影响不成比例,应接受针对性的早期检测、预防和意识项目。
- 高危HPV亚型与移植受者生殖器鳞状细胞癌相关。
- 需要进一步研究以确定HPV感染的重要危险因素并评估移植前HPV疫苗接种在预防皮肤生殖器恶性肿瘤中的效用。
研究设计与样本
- 回顾性综述,纳入2011年11月1日至2017年4月28日在学术转诊中心接受全身皮肤检查的496例实体器官移植受者。
- 研究分为两个时期:临床管理变更生效于2016年2月1日之前(era 1)和之后(era 2)。
- era 1评估376例移植受者(平均[SD]年龄60岁;年龄范围32-94岁;45例[65.2%]男性;164例[43.6%]白人)。
- era 2评估120例移植受者(平均年龄56岁;年龄范围22-79岁;76例[63.3%]男性;30例[25.0%]白人)。
- 所有临床怀疑恶性肿瘤的病变均行活检并进行HPV聚合酶链反应分型。
主要发现
- 120例移植受者中111例(92.5%)在病史采集部分否认存在生殖器病变。
- 53例移植受者(44.2%)发现生殖器病变,6例(5.0%)发现皮肤恶性肿瘤(基底细胞癌和原位鳞状细胞癌),3例(4.2%)发现生殖器原位鳞状细胞癌,29例(24.2%)发现尖锐湿疣。
- 12例原位鳞状细胞癌病变中8例(66.7%)高危HPV阳性,其中7例HPV-16和HPV-18阳性,1例高危HPV DNA阳性但无法进一步分型。
临床怎么用
- 作者建议所有实体器官移植受者应将生殖器皮肤彻底检查作为移植后常规皮肤检查的一部分。
- 作者建议深色皮肤类型患者应接受针对性的早期检测、预防和意识项目,重点关注移植后生殖器皮肤癌风险。
局限性
- 需要进一步研究以确定HPV感染的重要危险因素并评估移植前HPV疫苗接种在预防皮肤生殖器恶性肿瘤中的效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Squamous cell carcinoma (SCC) is the most common skin cancer diagnosed in solid organ transplant recipients (OTRs) and confers significant mortality. The development of SCC in the genital region is elevated in nonwhite OTRs. Viral induction, specifically human papillomavirus (HPV), is hypothesized to play a role in the pathophysiology of these lesions. OBJECTIVE: To assess the prevalence and types of genital lesions observed in OTRs. DESIGN, SETTING, AND PARTICIPANTS: This retrospective review included 496 OTRs who underwent full skin examination from November 1, 2011, to April 28, 2017, at an academic referral center. The review was divided into 2 distinct periods before a change in clinical management that took effect on February 1, 2016 (era 1) and after that change (era 2). Patient awareness of genital lesions was assessed. All lesions clinically suggestive of malignant tumors were biopsied and underwent HPV polymerase chain reaction typing. MAIN OUTCOMES AND MEASURES: Number and types of genital lesions, proportion of malignant tumors positive for HPV, and patients cognizant of genital lesions. RESULTS: Of the total 496 OTRs, 376 OTRs were evaluated during era 1 (mean [SD] age, 60 years; age range, 32-94 years; 45 [65.2%] male; 164 [43.6%] white) and 120 OTRs were evaluated during era 2 of the study (mean age, 56 years; age range, 22-79 years; 76 [63.3%] male; 30 [25.0%] white). Overall, 111 of the 120 OTRs (92.5%) denied the presence of genital lesions during the history-taking portion of the medical examination. Genital lesions were found in 53 OTRs (44.2%), cutaneous malignant tumors (basal cell carcinoma and SCC in situ) in 6 (5.0%), genital SCC in situ in 3 (4.2%), and condyloma in 29 (24.2%). Eight of the 12 SCC in situ lesions (66.7%) were positive for high-risk HPV. Seven tested positive for HPV-16 and HPV-18, and 1 tested positive for high-risk HPV DNA but could not be further specified. CONCLUSIONS AND RELEVANCE: Genital lesions in OTRs are common, but awareness is low. All OTRs should undergo thorough inspection of genital skin as a part of routine posttransplant skin examinations. Patients with darker skin types are disproportionately affected by cutaneous genital malignant tumors and should undergo a targeted program of early detection, prevention, and awareness focused on the risk of genital skin cancer after transplant. High-risk HPV subtypes are associated with genital SCC in OTRs. Additional studies are warranted to identify significant risk factors for HPV infection and to assess the utility of pretransplant HPV vaccination in the prevention of cutaneous genital malignant tumors.
引用
- Nadhan KS, Larijani M, Abbott J, et al. Prevalence and Types of Genital Lesions in Organ Transplant Recipients. JAMA Dermatol. 2018. PMID: 29387873. doi:10.1001/jamadermatol.2017.5801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。